May 20,2022

Dexcom and Abbott’s fight over glucose monitoring patents intensifies in Europe

Dexcom and Abbott are embroiled in a patent dispute over their glucose monitoring devices, with a focus on the UK, Germany, and the US. In Europe, the dispute began when Dexcom filed infringement suits on four of its patents against Abbott in Germany. Abbott counterclaimed by asserting infringement of its patents against Dexcom. The Regional Court Mannheim dismissed one of Abbott's cases against Dexcom due to insufficient evidence of infringement but Abbott has appealed. The legal battle continues, with more cases in progress. In the UK, both companies have challenged each other's patents. The UK High Court is set to try twelve patents across three technical trials, planned for December 2022, April 2023, and July 2023.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 12,2023

Glucotrack Announces Preclinical Testing With Implantable Continuous Glucose Monitor

Glucotrack, a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another milestone in its development of an implantable continuous glucose monitor (CGM) by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study demonstrating that the CGM sensor design is capable of measuring glucose for at least two years post-implant. The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 09,2023

Continuous Glucose Monitoring Market Size & Share Surpass USD 2 billion by 2028 – Exclusive Report by Transparency Market Research

The continuous glucose monitoring market revenues are expected to rise at a CAGR of 9.5% from 2021 to 2028, and projected to reach US$ 2 billion by 2028, according to the research publisher. Increasing demand for smart wearables and increasing incidence of chronic diseases are expected to drive the market in the coming years.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023

InsideTracker & Nutrisense CGM Bundle: Take Control of Your Metabolic Health

InsideTracker and Nutrisense partnered to offer a budled service experience for Nutrisense users. With access to CGMs, expert nutritionist support, and the Nutrisense app, users can spot patterns and trends in their glucose data by observing real-time glucose responses to food, stress, exercise, sleeping habits, and much more. In the bundle, subscribers will get access InsideTracker's Ultimate Plan including comprehensive blood testing, analysis, and wellness plan, and InnerAge 2.0 calculation for biological age based on personal blood biomarker data. At the same time, Nutrisense will be offering 2 CGM sensors, 1:1 nutritionist support and 1 month subscription in the Nutrisense app in the bundle package.

COLLABORATION PARTNERSHIP

#product & service

#cgm

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 05,2023 TOP STORY

Next-Generation Dexcom G7 Continuous Glucose Monitoring System Now Available in Canada

Dexcom announced today that its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System will be available on October 10, 2023, for Canadians living with all types of diabetes ages two and older, including those who are pregnant. The Dexcom G7 CGM System will be available to purchase in pharmacies across Canada as of Tuesday, October 10, 2023. Dexcom G7 offers real-time glucose readings sent automatically to a compatible display device, and a predictive alert that alerts users up to 20 minutes in advance of severe hypoglycemia for prevention.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 02,2023 TOP STORY

Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD

Dexcom announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany. New results from the COMISAIR seven-year study, the longest prospective real-world CGM study ever conducted, show significant and continued reduction of HbA1c with the use of real-time CGM by people with Type 1 diabetes. Regardless of insulin delivery method, multiple daily injections or insulin pump therapy, real-time CGM has greater and statistically significant HbA1c reduction when compared to self-monitoring blood glucose over seven years. The COMISAIR study also shows further substantial reduction in HbA1c when real-time CGM is connected to an automated insulin delivery system, specifically Tandem Control IQ. Dexcom announced the Dexcom G7 CGM system will begin launching with the Tandem t:slim X2 insulin pump before the end of the year in the U.S. and multiple markets across Europe and Asia-Pacific. This news follows the recent launch of the Omnipod 5 Automated Insulin Delivery System connected to Dexcom G6 in the UK and Germany.

CLINICAL STUDY

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Oct 03,2023 TOP STORY

Phillips-Medisize Teams with GlucoModicum to Develop an Innovative Needle-Free Continuous Glucose Monitor

Phillips-Medisize, a Molex company, and a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, invitro diagnostic and medtech devices, has teamed with GlucoModicum, an innovative medtech company based in Finland, to design and eventually commercialize a proprietary non-invasive, wearable device that removes technology and patient-care roadblocks to continuous glucose monitoring (CGM). In seeking a more convenient, rapid and gentle CGM alternative, GlucoModicum discovered that magnetohydrodynamic (MHD) technology could be used to apply a small amount of energy directly to interstitial fluid to drive it to the surface of the skin for quick and easy extraction of a glucose sample. GlucoModicum sought an experienced contract development and manufacturing organization (CDMO) to assist in realizing their vision for a new device, called Talisman. The device is not yet FDA approved and does not have the CE mark.

COLLABORATION PARTNERSHIP

#r&d

#cgm

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023 TOP STORY

Dexcom and SocialDiabetes Join Forces to Make Diabetes Management More Accessible

Dexcom and SocialDiabetes have joined forces to help people with diabetes improve their control over the disease. Through this international agreement, Dexcom device data is integrated into the SocialDiabetes platform along with other relevant health data such as insulin dosing data recorded by Smartpens, nutritional information and physical activity collected from various wearables; providing both patients and professionals with a complete metabolic map.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 30,2023 TOP STORY

SIBIONICS to Make Debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD)

Making its debut at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD), Shenzhen Sibionics Technology Co., Ltd. will unveil its flagship product, the SIBIONICS GS1 Continuous Glucose Monitoring System. Established in 2015, SIBIONICS is a high-tech firm specializing in the integration of implantable medical hardware technology and artificial intelligence algorithms. SIBIONICS CGM captured a market share of nearly 20% within its inaugural year of launch in China, making it the leading domestically produced CGM, offering calibration-free and scan-free features, as well as 14 days of real-time continuous monitoring. The product is on the verge of obtaining CE certification from the European Union. Additionally, SIBIONICS will present the SiBio KS1 Continuous Ketone Monitoring (CKM) System, a bio-wearable for metabolic management powered by SIBIONICS CGM technology, offering continuous real-time monitoring ketone levels up to 14 days.

PRODUCT

#cgm

#connected device

View Analyst & Ambassador Comments
Go to original news
Sep 26,2023 TOP STORY

Senseonics Announces the Last Patient Completion of the 365-Day ENHANCE Pivotal Clinical Study

Senseonics, a medical technology company focused on the development of implantable continuous glucose monitoring (CGM) systems, today announced the completion of the ENHANCE Pivotal Clinical Study adult cohort following the recently completed 365-day visit for the final study patient. The ENHANCE study is designed to evaluate the accuracy and safety of the Eversense system for one year. Over 165 adult subjects were inserted with Eversense systems in four centers across the United States. Data gathered in this study was also used to support the FDA submission for the integrated continuous glucose monitoring, iCGM, designation earlier in 2023. An investigational device exemption (“IDE”) supplement was submitted and approved for expansion of the study to allow for pediatric patients 14 to 18 years of age and the first pediatric study participants were enrolled in Q2 2023.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM